Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Women's Clinical Trials & CROs Market Forecast to More Than Double by 2036 as Precision Medicine Reshapes Trial Design

globenewswire.com
PFE Pfizer is mentioned as a company whose adaptation to market changes in women's clinical trials is analyzed in a report, suggesting its involvement in the evolving landscape. NVS Novartis is mentioned as a company whose adaptation to market changes in women's clinical trials is analyzed in a report, suggesting its involvement in the evolving landscape. MRK Merck is mentioned as a company whose adaptation to market changes in women's clinical trials is analyzed in a report, suggesting its involvement in the evolving landscape. JNJ Johnson & Johnson is mentioned as a company whose adaptation to market changes in women's clinical trials is analyzed in a report, suggesting its involvement in the evolving landscape.

Women's Clinical Trials & CROs Market Forecast to More Than Double by 2036 as Precision Medicine Reshapes Trial Design Dublin, June 23, 2026 (GLOBE NEWSWIRE) -- The "Women's Clinical Trials & CROs Market Report 2026-2036" has been added to ResearchAndMarkets.com's offering.

The report's release comes as the women's health research landscape undergoes structural change. The global women's clinical trials and CRO market is valued at $9.9 billion in 2026 and forecast to reach $22.3 billion by 2036, growing at a CAGR of 8.5%. This trajectory is being driven by the rising prevalence of women-predominant conditions, expanding regulatory requirements for sex-specific safety evaluation, and growing adoption of precision medicine and biomarker-driven approaches across reproductive health, oncology, and hormonal disorder indications.

Technological change is accelerating this shift. As oncology, immunology, reproductive health, and endocrine research move toward molecularly defined patient subgroups, women's health trials increasingly depend on genomic assays, hormonal biomarkers, and pharmacogenomics that vary across female life stages. Decentralized trial models are reinforcing this trend: in 2025, Lindus Health launched hybrid women's health trials in oncology and reproductive medicine, leveraging more than 30 million electronic health records to double enrollment speed compared with traditional CRO approaches. In response, CROs are expanding integrated biomarker services, genomic data platforms, and adaptive trial operational systems to meet sponsor demand.

The market is also being reshaped by trade and policy dynamics. Because clinical trials depend on imported laboratory reagents, specialized medical devices, and biomanufacturing inputs, the sector carries exposure to tariff-related cost escalation, particularly in women's health, where pregnancy-safe diagnostic tools and hormone-testing kits often come from limited supplier bases. The report notes that U.S.-China tariff friction is already disrupting biospecimen flows and central laboratory operations, prompting some sponsors to shift recruitment and site activation toward CRO networks in India, Southeast Asia, and Europe.

Why This Report Matters

For pharmaceutical sponsors, CROs, and investors, this combination of accelerating biomarker-driven demand and rising operational complexity from tariff exposure makes competitive positioning more consequential than ever. The report's analysis of how companies including Pfizer, Novartis, Merck, Johnson & Johnson, and WuXi AppTec are adapting their capabilities gives stakeholders a basis for identifying where outsourcing opportunities and operational risk are converging across the forecast period.

The full report, "Women's Clinical Trials & CROs Market Report 2026-2036," is available now in PDF format, with bespoke intelligence and customization options also offered by the publisher.

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/9gxczn

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.